An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

Global data are in the same ballpark as Chinese results presented earlier this year.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.

Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.

A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.